FibroGen Announces Executive Compensation Changes
Ticker: KYNB · Form: 8-K · Filed: Sep 13, 2024 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, employment-agreement
TL;DR
FibroGen inked a new deal with its CMO, Dr. Zerhouni. Details on pay inside.
AI Summary
FibroGen, Inc. announced on September 12, 2024, changes in its executive compensation arrangements. Specifically, the company entered into a new employment agreement with its Chief Medical Officer, Dr. Elias V. Zerhouni, effective September 12, 2024. This agreement outlines his compensation and other terms of employment.
Why It Matters
Changes in executive compensation can signal shifts in company strategy or confidence in leadership, potentially impacting investor sentiment and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns executive employment agreements and compensation, which typically have a low direct impact on the company's overall operations or financial health.
Key Players & Entities
- FibroGen, Inc. (company) — Registrant
- Dr. Elias V. Zerhouni (person) — Chief Medical Officer
- September 12, 2024 (date) — Effective date of new employment agreement
FAQ
What are the key terms of the new employment agreement with Dr. Elias V. Zerhouni?
The filing states that a new employment agreement was entered into with Dr. Elias V. Zerhouni, effective September 12, 2024, outlining his compensation and other terms of employment, but specific details of the agreement are not provided in this summary.
When did the new employment agreement with Dr. Zerhouni become effective?
The new employment agreement with Dr. Elias V. Zerhouni became effective on September 12, 2024.
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is FibroGen, Inc.'s principal executive office address?
FibroGen, Inc.'s principal executive office is located at 409 Illinois Street, San Francisco, California, 94158.
What is FibroGen's Standard Industrial Classification (SIC) code?
FibroGen's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 661 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-09-13 16:12:08
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se
Filing Documents
- fgen-20240912.htm (8-K) — 37KB
- 0000950170-24-106359.txt ( ) — 148KB
- fgen-20240912.xsd (EX-101.SCH) — 24KB
- fgen-20240912_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FIBROGEN, INC. Date: September 13, 2024 By: /s/ Michael Lowenstein Michael Lowenstein Chief Legal Officer